Meaghan Tenney, MD
Gynecologic Oncology · Atlanta, GANPI 1356502959
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $459 of the $547 with a category attached, or 83.9%. It is spread thinly across 10 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $298 and has fallen 82.6% since, to $52 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in GA, where the typical reported total is $3,080.
Across 18 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- THD America, Inc.$123
- GSK$110
- Clovis Oncology, Inc.$88
- Eisai Inc.$72
- Smith+Nephew$31
- Myriad Genetic Laboratories, Inc.$31
- plus $91 from 4 others
Across 79 payments — averaging $6026.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$139K
- Clovis Oncology, Inc.$123K
- GSK$54K
- AbbVie$50K
- Pharmaand GmbH$44K
- Astrazeneca UK Limited$20K
- plus $47K from 5 others
What the payments were for
- Food & beverage$45984%
- Education$8816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| THD America, Inc. | 1 | $123 |
| GSK | 4 | $110 |
| Clovis Oncology, Inc. | 2 | $88 |
| Eisai Inc. | 3 | $72 |
| Smith+Nephew | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Pfizer | 2 | $29 |
| Merck | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Tesaro, Inc. | 1 | $18 |
How this compares
$547 in reported general payments places this provider in the 15th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 17 | $322 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $247 |
| Ondansetron OdtOndansetron | 25 | $136 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $125 |
| Gabapentin | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Atlanta
- Benedict BenignoAtlanta$273K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Guilherme CantuariaAtlanta$13K
- Cyril SpannAtlanta$12K
- Kevin AultAtlanta$10K
- Leda GattocAtlanta$7K
- Jennifer ScaliciAtlanta$6K
- Oi Wah YapAtlanta$3K
- Namita KhannaAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.